Selective inhibitor of transforming growth factor-β
receptor I (ALK5, TGF-β
= 14.3 nM). Inhibits TGF-β
1-induced smad2/3 nuclear localization and TGF-β
RI-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of GlaxoSmithKline
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis.
Grygielko et al.
Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis
Higashiyama et al.
Tumor-specific efficacy of transforming growth factor-βRI inhibition in eker rats.
Laping et al.
Clin.Cancer Res., 2007;13:3087
The citations listed below are publications that use Tocris products. Selected citations for SB 525334 include:
Showing Results 1 - 5 of 5